Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Effect of delapril–manidipine combination vs irbesartan–hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus

Journal of Human Hypertension volume 18, pages 687–691 (2004)Cite this article

Abstract

The aim of this double-blind, double-dummy, parallel group study was to compare the effects of delapril–manidipine combination vs a irbesartan–hydrochlorothiazide combination on plasma tissue plasminogen activator (t-PA) and plasmogen activator inhibitor type I (PAI-l) activities in hypertensive patients with type II diabetes mellitus. After a 4-week run-in placebo period, 80 patients (37 male and 43 female), aged 41–65 years, were randomly allocated to an 8-week treatment with delapril 30 mg once daily or irbesartan 150 mg once daily. Thereafter, manidipine l0 mg once daily was added to delapril treatment and hydrochlorothiazide 12.5 mg to irbesartan treatment for a further 8 weeks. Blood pressure (BP), plasma t-PA and PAI-l activities were evaluated at the end of the run-in period, after 4-week monotherapy treatments, and at the end of the combination treatment periods. Both combination treatments, delapril–manidipine and irbesartan–hydrochlorothiazide, produced a greater reduction in systolic BP/diastolic BP (SBP/DBP) values (−27.6/21.8 mmHg and −26.4/20.2 mmHg, respectively) than the respective monotherapies (−15.2/11.7 mmHg with delapril and −16.3/11.3 mmHg with irbesartan). Delapril monotherapy significantly decreased plasma PAI-l activity (−10.4 IU/mI; P<0.05). The addition of manidipine produced a significant increase in t-PA activity (+0.27 IU/mI); P<0.05). Irbesartan monotherapy did not significantly affect the fibrinolytic balance, whereas the addition of hydrochlorothiazide worsened it, producing a significant increase in PAI-l activity (+9.5 IU/ml; P<0.05). In hypertensive patients with type II diabetes mellitus, the combination delapril–manidipine may determine a greater improvement of the fibrinolytic function than the respective monotherapy, while the association irbesartan–hydrochlorothiazide may worsen it.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Chobanion AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.

    Article  Google Scholar 

  2. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  3. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of microvascular and macrovascular complications in type II diabetes: UKPDS 38. Br Med J 1998; 317: 703–713.

  4. Hansson L et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1988; 351: 1755–1762.

    Article  Google Scholar 

  5. Heart Outcomes Prevention Evaluation (HOPE) Investigators. Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2000; 342: 145–153.

  6. Sowers JR . Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003; 16: 41S–45S.

    Article  PubMed  Google Scholar 

  7. Folsom AR et al. Prospective studies of markers of hemostatic function with risk of ischemic stroke. The atherosclerosis risk in communities (ARIC) study investigators. Circulation 1999; 100: 736–742.

    Article  CAS  PubMed  Google Scholar 

  8. Held C et al. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study, the angina prognosis study in Stockholm Atherosclerosis 2000; 148: 179–188.

    CAS  Google Scholar 

  9. Eliasson M, Jansson JH, Nilsson P, Asplund K . Increased levels of tissue plasminogen activator inhibitor antigen in essential hypertension: a population based study in Sweden. J Hypertens 1997; 15: 349–356.

    Article  CAS  PubMed  Google Scholar 

  10. Poli KA et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101: 264–269.

    Article  CAS  PubMed  Google Scholar 

  11. McGill JB et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104–109.

    Article  CAS  PubMed  Google Scholar 

  12. Meigs JB et al. Hyperinsulinemia, hyperglycemia and impaired hemostasis: the Framingham Offsprings Study. JAMA 2000; 283: 221–228.

    Article  CAS  PubMed  Google Scholar 

  13. Lottermoser K et al. Antihypertensive drug treatment and fibrinolytic function. Am J Hypertens 1998; 11: 378–384.

    Article  CAS  PubMed  Google Scholar 

  14. Chohan IS, Singh J, Vermylen J, Verstraete M . Effect of furosemide on plasma fibrinolytic activity and urokinase excretion. Exp Haemat 1977; 5: 153–157.

    CAS  Google Scholar 

  15. Pedersen OD et al. Regulation of tissue-type plasminogen activator inhibitor type-1 in patients with ischemic heart disease:possible unfavourable effect of diuretics. Coronary Artery Disease 1994; 5: 617–623.

    Article  CAS  PubMed  Google Scholar 

  16. Winther K . The effect of beta-blockade on platelet function and fibrinolytic activity. J Cariovasc Pharmacol 1987; 10(Suppl 2): S94–S98.

    Google Scholar 

  17. Wright RA et al. The long-term effect of metoprolol and epanolol on tissue type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischemic heart disease. Eur J Clin Pharmacol 1994; 46: 279–282.

    Article  CAS  PubMed  Google Scholar 

  18. Gleerup G, Winther K . Decreased fibrinolytic activity and increased platelet function in hypertension. Am J Hypertens 1991; 4: 168S–171S.

    Article  CAS  PubMed  Google Scholar 

  19. Gleerup G et al. Does antihypertensive therapy affect the natural protection against thrombosis? J Cardiovasc Pharmacol 1991; 18(Suppl 3): S34–S36.

    Article  PubMed  Google Scholar 

  20. Wright RA et al. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67–73.

    Article  CAS  PubMed  Google Scholar 

  21. Vaughan DE et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997; 96: 442–447.

    Article  CAS  PubMed  Google Scholar 

  22. Brown NJ, Agirbasli M, Vaughan DE . Comparative effect of angiotensin emzyme inhibition and angiotensin II type I receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999; 34: 285–290.

    Article  CAS  PubMed  Google Scholar 

  23. Fogari R et al. Effect of losartan and perindopril on plasma PAI-1 and fibrinogen in hypertensive type II diabetic patiens. J Hypertens 1999; 17(Suppl 3): P1.134 S58 (Abstract).

    Google Scholar 

  24. Fogari R et al. Differential effects of ACE-inhibition and Angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive post-menopausal women. Am J Hypertens 2001; 14: 921–926.

    Article  CAS  PubMed  Google Scholar 

  25. Seljeflot I et al. Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension. Hypertension 1996; 27: 1299–1304.

    Article  CAS  PubMed  Google Scholar 

  26. Oikawa T et al. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the antifibrotic effect of renin-angiotensin inhibition. Kidney Int 1997; 51: 164–172.

    Article  CAS  PubMed  Google Scholar 

  27. Erdem Y et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 11: 1071–1076.

    Article  Google Scholar 

  28. Razzetti A, Acerbi D . Pharmacokinetic and pharmacological properties of delapril, a lipophilic, non sulphydril ACE inhibitor. Am J Cardiol 1995; 75: 7F–12F.

    Article  CAS  PubMed  Google Scholar 

  29. Cheer SM, McClellan K . Manidipine. Drugs 2001; 61: 1777–1799.

    Article  CAS  PubMed  Google Scholar 

  30. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 281: 1039–1057.

  31. Kluft C et al. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fasting acting inhibitor (PAI-1). Thromb Haemost 1989; 59: 329–332.

    Google Scholar 

  32. Randy M, Sundell IB, Nilssan TK . Blood collection in strong acid citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989; 62: 917–922.

    Article  Google Scholar 

  33. Eriksson E, Tengborn L, Risberg B . The effect of various anticoagulant/antiplatelet mixtures on determination of plasminogen activator inhibitor, platelet proteins and hemostasis parameters. Thromb Haemost 1989; 61: 511–516.

    CAS  PubMed  Google Scholar 

  34. Wiman B, Mellbring G, Randy M . Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127: 279–288.

    Article  CAS  PubMed  Google Scholar 

  35. Chmielewska J, Randy M, Wiman B . Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427–436.

    Article  CAS  PubMed  Google Scholar 

  36. Ridker PM et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Circulation 1993; 87: 1969–1973.

    Article  CAS  PubMed  Google Scholar 

  37. Vaughan DE, Lazos A, Tong K . Angiotensin II regulates the expression of plasminofer activator inhibitor 1 in cultured endothelial cells. A potential link between the renin–angiotensin system and thrombosis. J Clin Invest 1995; 95: 995–1001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Brown NJ, Nadeau J, Vaughan DE . Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997; 77: 522–525.

    Article  CAS  PubMed  Google Scholar 

  39. Juhan-Vague I, Alessi MC . Pai-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656–660.

    Article  CAS  PubMed  Google Scholar 

  40. Fogari R et al. Ace-inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32: 616–620.

    Article  CAS  PubMed  Google Scholar 

  41. Kerins DM, Hao Q, Vaughan DE . Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapaptide Angiotensin IV. J Clin Invest 1995; 96: 2515–2520.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM . Comparison of angiotensin converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharmacol 1993; 22: 579–584.

    Article  CAS  PubMed  Google Scholar 

  43. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J . Secretion of plasminogen activator inhibitor 1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067–1073.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Therapeutics, Clinica Medica II, IRCCS Policlinico S Matteo, University of Pavia, Pavia, Italy

    A Mugellini, P Preti, A Zoppi, L Corradi, E Fogari, G Derosa & R Fogari

Authors
  1. A Mugellini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Preti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Zoppi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Corradi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Fogari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Derosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Fogari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Fogari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mugellini, A., Preti, P., Zoppi, A. et al. Effect of delapril–manidipine combination vs irbesartan–hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J Hum Hypertens 18, 687–691 (2004). https://doi.org/10.1038/sj.jhh.1001726

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001726

Keywords

This article is cited by

Search

Advanced search

Quick links